Deuremidevir hydrobromide (VV116) is a promising antiviral against human metapneumovirus
Huilong Wang1, Haoli Yi2, Tianwen Hu3
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Abstract:
Human metapneumovirus (hMPV) is a major respiratory pathogen for which no specific antiviral therapy is approved. In this study, we evaluated the anti-hMPV activity of the oral nucleoside analog VV116. In vitro, VV116 strongly inhibited hMPV replication in LLC-MK2 cells, with a half-maximal effective concentration (EC50) of 0.79 μM and a high selectivity index (SI) > 159. In hMPV-infected mice, oral administration of VV116 significantly reduced viral loads in lung and nasal turbinate tissues in a dose-dependent manner and ameliorated virus-induced lung pathology. Our findings provide the first report of the remarkable anti-hMPV activity of VV116, supporting its therapeutic promise and warranting further clinical application.
More Related Videos
09:31Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
Published on: April 15, 2017
09:29Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Related Concept Videos
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...
Inhibitors of Viral Protein Synthesis
Subviral Agents
Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
Human Virome
Cytomegalovirus Disease
